Tag: Dr Elias Zerhouni

dupilumab

Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...

"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."

Connect with Us

38,194FansLike
595FollowersFollow
2,663FollowersFollow
5,444FollowersFollow
38SubscribersSubscribe